There's a lot going on in the benefits industry right now for advisors to be excited about, including new cost-containment strategies, new technology, new vendors, and new products. And one topic that can't be ignored: the role of AI in the benefits industry.

A Centene executive estimates fewer than 25% of the arrangement users get covered through the ACA exchange system.

Fixing messy data after it arrives is a trap.

Regeneron will provide Otarmeni — a new gene therapy for an ultra-rare form of genetic hearing loss recently approved by the U.S. Food and Drug Administration — for free under a new agreement with the U.S. government.